Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bivalirudin for Coronary Microcirculation in High-Risk PCI
NCT05984537Phase 4Recruiting
- Sponsor
- Peking University First Hospital
- Start
- Jul 2023
- Primary completion
- Dec 2025
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of bivalirudin in Coronary Microvascular Dysfunction (CMD), sponsored by Peking University First Hospital. Started Jul 2023; status: recruiting.
02
Drugs
bivalirudin
03
Conditions
Coronary Microvascular Dysfunction (CMD)
Beyond the preview
Go deeper on NCT05984537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05984537.